Atopic Dermatitis (AD; also known as Eczema) is the most frequent chronic relapsing inflammatory skin disease that affect up to 20% children in school age and 6-10% adult. AD is a multifactorial and complex disease, characterized by an impaired (“leaky”) skin barrier and abnormal immune response. Because of its chronic and relapsing course, intense itch and frequent skin infection, AD significantly affects the quality of life of our patients and their families.
In the specialty clinic, we are able to allow appropriate time with patients to discuss concerns, treatment plans and necessary counseling. Clinical encounters can be overwhelming for patients and the AD treatment plan often includes several products, different anatomical location and multiple daily applications. Our goal is to empower patients (and family/caregivers) by sharing the reasoning of the treatment and clearly discuss what is recommended and when to use different products. We will work together to reduce the burden of the diseases on our patients and ensure a better quality of life.
- Clinical expertise to help recognize and distinguish AD from other common dermatologic disorders.
- Assess severity and burden of disease on both patients and caregivers/family.
- Select individualized treatment plans for patients with AD using evidence-based and expert recommendations.
- Engage in shared decision-making and disease education discussions with AD patients and their caregivers
- Assistance with Insurance and Pharmacy processes.
- Opportunity to participate in the latest clinical trials and have access to the most effective treatments.
- Continued follow-up to assess patient changing needs.
- Opportunity to offer multidisciplinary care working with other UF experts (e.g. Patch test, Allergy, Integrative Medicine)
Dr. De Benedetto
Williamson S, Merritt J, De Benedetto A. Atopic dermatitis in the elderly: a review of clinical and pathophysiological hallmarks. Br J Dermatol. 2019 Mar 21. doi: 10.1111/bjd.17896.
De Benedetto A, Kubo A, Beck LA. Skin barrier disruption: a requirement for allergen sensitization? J Invest Dermatol. 2012 Mar;132(3 Pt 2):949-63. doi: 10.1038/jid.2011.435.
Lebwohl M, Alexis AF, Beck LA et al. Systemic Therapies for Moderate-to-Severe Atopic Dermatitis: Expert Perspectives in Practice J Drugs Dermatol. 2019 Feb 1;18(2):122-129.
Davidson WF, Leung DYM, Beck LA, et al. Report from the National Institute of Allergy and Infectious Diseases workshop on “Atopic dermatitis and the atopic march: Mechanisms and interventions”. J Allergy Clin Immunol. 2019 Mar;143(3):894-913.
Yang EJ, Beck KM, Sekhon S, Bhutani T, Koo J. The impact of pediatric atopic dermatitis on families: A review. Pediatr Dermatol. 2019 Jan;36(1):66-71.
Silverberg JI. Public Health Burden and Epidemiology of Atopic Dermatitis. Dermatol Clin. 2017 Jul;35(3):283-289.